Intravesical bacille Calmette-Guerin in stage T1 grade 3 bladder cancer therapy: A 7-year follow-up

Urology

Volumn 54, Issue 2, 1999, Pages 258-263

  Hurle, Rodolfo ^a   Losa, Andrea ^a   Manzetti, Alberto ^a   Lembo, Antonio ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER MORTALITY; CANCER STAGING; CARCINOMA IN SITU; FEMALE; FOLLOW UP; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT CANCER; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; BCG VACCINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SURVIVAL RATE; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 0032765928     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00116-8     Document Type: Article

References (31)

1. Lamm D.L., Blumenstein B.A., Crawford E.D., et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med. 325:1991;1205-1209.
2. Herr H.W., Wartinger D.D., Fair W.R., et al. Bacillus Calmette-Guérin therapy for superficial bladder cancer a 10-year followup . J Urol. 147:1992;1020-1023.
3. Pagano F., Garbeglio A., Milani C., et al. Prognosis of bladder cancer. I. Risk factors in superficial transitional cell carcinoma. Eur Urol. 13:1987;145-149.
4. Hurle R., Losa A., Ranieri A., et al. Low dose Pasteur bacillus Calmette-Guérin regimen in stage T1, grade 3 bladder cancer therapy. J Urol. 156:1996;1602-1605.
5. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-462.
6. Mehta C.R., Patel N.R. A network algorithm for performing Fisher's exact test in r × c contingency tables. J Am Stat Assoc. 78:1983;427-434.
7. Cox D.R. Regression models and life-tables. J R Stat Soc Series B. 34:1972;187-192.
8. Holmang S., Hedelin H., Anderstrom C., et al. The importance of depth of invasion in stage T1 bladder carcinoma a prospective cohort study . J Urol. 157:1997;800-804.
9. Bracken R.B., McDonald M.W., Johnson D.E. Cystectomy for superficial bladder cancer. Urology. 18:1981;459-463.
10. Stöckle M., Alken P., Engelman U., et al. Radical cystectomy - often too late? Eur Urol. 13:1987;361-367.
11. Pagano F., Bassi P., Galletti T.P., et al. Results of contemporary radical cystectomy for invasive bladder cancer a clinicalpathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification . J Urol. 145:1991;45-50.
12. Amling C.L., Thrasher J.B., Frazier H.A., et al. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol. 151:1994;31-36.
13. Freeman J.A., Ersig D., Stein J.P., et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer. 76:1995;833-837.
14. Lamm DL, Blumenstein B, Sarosdy M, et al: Significant long-term patient benefit with BCG maintenance therapy: a Southwest Oncology Group study (abstract). J Urol 157 (part 2): 213A, 1997.
15. Jaske G., Loid W., Seeber G., et al. Stage T1, grade 3 transitional cell carcinoma of the bladder an unfavorable tumor? J Urol. 137:1987;39-43.
16. Rubben H., Allhoff E.P., Marquardt H., et al. Registry for Urinary Tract Tumors RWTH Aachen (RUTTAC 1985), 7th Jahresbericht. Verh Dtsch Gesell Urol. 36:1985;737-742.
17. Torti F.M., Lum B.L., Aston D., et al. Superficial bladder cancer the primacy of grade in the development of invasive disease . J Clin Oncol. 5:1987;125-130.
18. Klan R., Hardung R., Meier T., et al. Progression in T1G3 urothelial bladder cancer impact of therapy . J Urol. 153:(part 2):1995;234A. (abstract).
19. Cookson M.S., Sarosdy M.F. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guérin therapy. J Urol. 148:1992;797-801.
20. Meng M.V., Sanda M.G. Comparison of intravseical BCG to radical cystectomy for high grade, T1 transitional cell carcinoma using Markov decision tree analysis. J Urol. 153:(part 2):1995;466A. (abstract).
21. Pansadoro V., Emiliozzi P., Defidio L., et al. Bacillus Calmette-Guérin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder long-term results . J Urol. 154:1995;2054-2058.
22. Zhang G.K., Uke E.T., Sharer W.C., et al. Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder. J Urol. 155:1996;1907-1909.
23. Palou J., Rosales A., Chechile G., et al. Long term followup of 98 patients with T1G3 transitional cell carcinoma of the bladder treated with BCG. Br J Urol. 80:(suppl 2):1997;36. (abstract).
24. Herr H.W. Tumour progression and survival in patients with T1G3 bladder tumours 15-year outcome . Br J Urol. 80:1997;762-765.
25. Lebret T., Gaudez F., Hervè J.M., et al. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours recurrence, progression and success . Eur Urol. 34:1998;64-72.
26. Cookson M.S., Herr H.W., Zhang Z.F., et al. The treated natural history of high risk superficial bladder cancer 15-year outcome . J Urol. 158:1997;62-67.
27. Herr H.W. Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol. 16:1998;1099-1102.
28. Herr H.W., Cookson M.S., Soloway S.M. Upper tract tumors in patients with primary bladder cancer followed for 15 years. J Urol. 156:1996;1286-1287.
29. Farrow G.M., Utz D.C., Rife C.C., et al. Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder. Cancer Res. 37:1977;2794-2797.
30. Hurle R., Losa A., Manzetti A., et al. Upper urinary tract tumors developing after treatment of superficial bladder cancer 7-year follow-up of 591 consecutive patients . Urology. 53:1999;1144-1148.
31. Herr H.W., Laudone V.P., Badalament R.A., et al. BCG therapy alters the progression of superficial bladder cancer. J Clin Oncol. 6:1988;1450-1455.